Technology
Health
Medical
Helius Medical
$2.559876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.55
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.10 (4.08%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Helius Medical and other stocks, options, ETFs, and crypto commission-free!
About
Helius Medical Technologies, Inc. operates as a medical technology company, which engages in the development of products for the treatment of neurological symptoms caused by disease and trauma. It focuses on licensing and acquiring platform technologies that amplify the brain's ability to heal itself. Read More The company was founded in 2014 and is headquartered in Newtown, PA.
Employees
25
Headquarters
Newtown, Pennsylvania
Founded
2014
Market Cap
65.90M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
109.89K
High Today
$2.59
Low Today
$2.45
Open Price
$2.45
Volume
25.09K
52 Week High
$13.20
52 Week Low
$1.77
Collections
Technology
Health
Medical
2018 IPO
US
North America
News
Yahoo FinanceMay 9
Helius Medical Technologies, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update; Reaffirms Full Year 2019 Outlook
NEWTOWN, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the first quarter ended March 31, 2019. First Quarter 2019 Financial Summary Revenue of $0.7 million, compared to no revenue in first quarter 2018. Operating loss of $6.8 million, compared to operating loss of $4.7 million in first quarter 2018. Net income of $1.3 million, compared to net...
Price Paid on Robinhood
24% Lower
Right Now
52 Week Low
$1.77
Average Price Paid
$3.37
52 Week High
$13.20
Earnings
-$0.22
-$0.17
-$0.11
-$0.06
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 8, Pre-Market